GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 5, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on June 5, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker executing share purchases
- 001-15170 (other) — SEC File Number
- 20250605 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares.
Who is acting as GSK's stockbroker for these transactions?
Merrill Lynch International is acting as GSK's corporate stockbroker.
On what date was this transaction information announced?
The announcement was made on June 5, 2025.
What type of shares did GSK purchase?
GSK purchased its ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased or the total cost?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but does not provide the specific quantity or dollar amount in the provided text.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 5, 2025 regarding GSK plc (GLAXF).